The murder of UHG CEO Brian Thompson was a tragic reflection of rising frustration with a failing healthcare system. In my latest Forbes, I explain why 2025 will be a turning point for providers to finally embrace a new, market-based business model. bit.ly/4g97fAu

On Wednesday, Congress introduced a bill to ban PBMs and insurers from owning pharmacies. In my latest Forbes, I explain why improved oversight and competition are crucial to ensuring value and choice for patients. #PBMs bit.ly/3BFtfE4

As we approach 2025, the pharmaceutical industry faces mounting pressures: rising costs, stricter regulation, and an increasing need to prioritize long-term value. How will manufacturers adapt? Read more in my latest Forbes. #Pharma2025 bit.ly/4iOl5ds

By passing a slimmed-down version of Congress’ latest funding package, Americans dodged a bullet. The proposed legislation would have only perpetuated harmful PBM practices. Read more in my latest Forbes. #PBMReform #Healthcare bit.ly/4gWRlt5

At the 11th hour, Congress tried to sneak flawed PBM reform into the 1,500-page CR HR II bill. Thankfully, it failed. Read more in my op-ed for RealClearHealth. #PBMReform #Congress bit.ly/40oA2fa

Growing resentment facing health insurers following the murder of UHG’s CEO reflects deep flaws in the healthcare ecosystem. Until we align incentives with patient outcomes, the broken cycle will continue. Read more Forbes. #HealthInsurance bit.ly/40gF0sV

On Tuesday, Senate Finance Committee voted to advance RFK Jr.’s nomination to lead the HHS.gov, sparking both praise and controversy. Regardless of the outcome, Kennedy has undeniably influenced the national conversation on healthcare. #MAHA #RFK Read more Forbes. bit.ly/3EDU6S3

As costs rise & claims are denied, trust in insurers is falling. Rebuilding it requires transparency, and realignment of incentives. Read more in my latest Forbes. #HealthInsurance bit.ly/4gHGDpU

The battle over utilization management is escalating. While meant to control costs, it often delays care, frustrates doctors, and leaves patients behind. What’s the solution? Read my latest Forbes. #healthinsurance bit.ly/4kflp5K

The latest wave of pharma layoffs reflects financial pressures reshaping the industry. Strategic cuts can streamline, but indiscriminate layoffs risk eroding knowledge & disrupting R&D. Read more in my latest Forbes. #Pharma #Layoffs bit.ly/3DHbCoE

There’s no quick fix to a market-based healthcare model, but greater transparency is essential. President Trump’s recent executive order is a step in the right direction. Read more Forbes. #HospitalPriceTransparency bit.ly/4kScHL7

President Trump’s latest #tariffs sent shockwaves through global markets. For #pharma, tariffs are critical to address the U.S.'s dangerous reliance on foreign APIs and the strength of our healthcare system. Read more about what’s at stake: bit.ly/4i8nPRa

Trump’s latest EO is ambitious in scope—tackling rising drug prices, misaligned incentives, and the “pill penalty.” Curious about what’s at stake? Read more here. #ExecutiveOrder #Healthcare bit.ly/42GQvLv

“Economic security and national security are almost directly related.” Jamie Dimon is right. Our pharma edge is at risk — and we’re ceding ground to rivals who don’t play fair. We need to reshore, reinvest, and rethink. More in my latest Forbes: bit.ly/42Eomof

Rural healthcare is collapsing—hospitals are closing, pharmacies disappearing. This isn’t just a health issue, it’s a national security risk. We need a smarter model. My latest in Forbes: bit.ly/3RHErEO

Great products fail at launch—not for lack of innovation, but because of poor evidence planning. In our latest article, we cover common IEP pitfalls: silos, misaligned populations, and payer segmentation. Read more here: bit.ly/4jtffxn

President Trump’s new drug pricing EO could reshape how Americans pay for medicine by tackling global trade imbalances and middlemen who inflate costs. It gives agencies power to enforce change. Could this be a game changer? Read more: bit.ly/43qJf70

#DOGE’s findings confirm what many of us have known for years: gov’t waste, fraud & abuse are rampant. Now, we must be strategic in our approach to reform. Cuts should be made with a scalpel, not an axe. Read more here: forbes.com/sites/ritanume…

Teva’s layoffs are the latest sign of growing pressure across the pharmaceutical sector. It’s a reminder that we need a smarter drug pricing model—one that supports innovation and affordability. bit.ly/43Kr24d

Medicaid cuts aren’t the crisis—the broken business model is. We pour billions into inefficiency while coverage slips further out of reach. It’s time to stop patching and start fixing. Read more in my latest for Forbes bit.ly/4kAHYS7